Clinical Trials
6 trialsNCT00079482 2016-07-21
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2 Completed
NCT00586651 2015-10-08
Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2 Completed
NCT00081601 2012-08-24
Study of CEP-701 in Treatment of Prostate Cancer
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2 Completed
NCT00030186 2012-08-23
Open Study of CEP-701 in Patients With Refractory Acute Myeloid Leukemia With FLT-3 Mutation
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2 Completed
NCT00242827 2012-08-23
Efficacy and Safety of Oral CEP-701 for the Treatment of Patients With Advanced Multiple Myeloma
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2 Terminated
NCT00494585 2012-06-25
CEP-701 for PH-negative Myelofibrosis
M.D. Anderson Cancer Center
Phase 2 Completed